Related Experiment Video
Updated: Apr 25, 2026

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells
Published on: July 30, 2020
The Aurora-A inhibitor MLN8237 affects multiple mitotic processes and induces dose-dependent mitotic abnormalities
Italia Anna Asteriti1, Erica Di Cesare1, Fabiola De Mattia1
1Institute of Biology, Molecular Medicine and Nanobiotechnology (formerly Institute of Molecular Biology and Pathology), CNR National Research Council, Sapienza University of Rome, Rome, Italy.
Abstract:
Inhibition of Aurora kinase activity by small molecules is being actively investigated as a potential anti-cancer strategy. A successful therapeutic use of Aurora inhibitors relies on a comprehensive understanding of the effects of inactivating Aurora kinases on cell division, a challenging aim given the pleiotropic roles of those kinases during mitosis. Here we have used the Aurora-A inhibitor MLN8237, currently under phase-I/III clinical trials, in dose-response assays in U2OS human cancer cells synchronously proceeding towards mitosis. By following the behaviour and fate of single Aurora-inhibited cells in mitosis by live microscopy, we show that MLN8237 treatment affects multiple processes that are differentially sensitive to the loss of Aurora-A function. A role of Aurora-A in controlling the orientation of cell division emerges. MLN8237 treatment, even in high doses, fails to induce efficient elimination of dividing cells, or of their progeny, while inducing significant aneuploidy in daughter cells. The results of single-cell analyses show a complex cellular response to MLN8237 and evidence that its effects are strongly dose-dependent: these issues deserve consideration in the light of the design of strategies to kill cancer cells via inhibition of Aurora kinases.
Insights
Aurora kinase inhibitors like MLN8237 impact cell division during mitosis. Cancer cell elimination is inefficient, with dose-dependent effects on aneuploidy, requiring careful therapeutic strategy design.
Area of Science:
- Cell Biology
- Molecular Oncology
- Cancer Therapeutics
Background:
- Aurora kinase inhibition is a promising anti-cancer strategy.
- Understanding Aurora kinase roles in mitosis is crucial for therapeutic success.
- MLN8237 is an Aurora-A inhibitor in clinical trials.
Purpose of the Study:
- To investigate the dose-dependent effects of Aurora-A inhibition on cell division using MLN8237.
- To elucidate the specific mitotic processes affected by Aurora-A inactivation.
- To assess the impact of MLN8237 on cell elimination and daughter cell aneuploidy.
Main Methods:
- Dose-response assays using MLN8237 in U2OS human cancer cells.
- Synchronous cell cycle progression towards mitosis.
- Live microscopy to track single-cell behavior and fate during mitosis.
Main Results:
- MLN8237 affects multiple mitotic processes with differential sensitivity to Aurora-A loss.
- Aurora-A plays a role in controlling cell division orientation.
- High-dose MLN8237 treatment does not efficiently eliminate dividing cells or their progeny.
- Significant aneuploidy is induced in daughter cells, with dose-dependent effects.
Conclusions:
- MLN8237 exhibits complex, dose-dependent effects on mitosis and cell fate.
- Inefficient cancer cell elimination and induced aneuploidy necessitate careful consideration for therapeutic strategies.
- Further research is needed to optimize Aurora kinase inhibitor-based cancer therapies.
More Related Videos
07:14Live Cell Imaging to Assess the Dynamics of Metaphase Timing and Cell Fate Following Mitotic Spindle Perturbations
Published on: September 20, 2019
08:33Combining Mitotic Cell Synchronization and High Resolution Confocal Microscopy to Study the Role of Multifunctional Cell Cycle Proteins During Mitosis
Published on: December 5, 2017
Related Concept Videos
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Drugs that Destabilize Microtubules
PI3K/mTOR/AKT Signaling Pathway
Destabilization of Microtubules
Drugs that Stabilize Microtubules
Anaphase Promoting Complex